T1	Participants 352 427	chemotherapy-naive patients who received moderately emetogenic chemotherapy
T2	Participants 494 669	patients naive to emetogenic chemotherapy (N = 1,085) who were scheduled to receive cyclophosphamide- (500 to 1,200 mg/m2) or carboplatin (> or = 300 mg/m2) based chemotherapy
